# Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

> **NCT02128282** · PHASE1,PHASE2 · COMPLETED · sponsor: **Senhwa Biosciences, Inc.** · enrollment: 127 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** CX-4945
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02128282
- **Lead sponsor:** Senhwa Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2020-11-06
- **Final completion:** 2021-08-05
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128282, "Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02128282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*